Recruiting newly referred lung cancer patients to a patient navigator intervention (PACO): lessons learnt from a pilot study

Abstract

Objectives: The incidence of and survival from lung cancer are associated with socioeconomic position, and disparities have been observed in both curative and palliative treatment for lung cancer. ‘Patient navigation’ is valuable in addressing health disparity, with timely treatment and transition to care. We conducted a pilot study to test the feasibility of a patient navigator program (PAtient COach) for newly diagnosed lung cancer. We present the trial, the findings from the pilot study and discuss factors that might have affected recruitment rates.

Material and methods: We invited 24 lung cancer patients referred for chemotherapy to the Oncology Department at Herlev University Hospital, Denmark, to participate in the pilot study. To be eligible, patients had to live alone, have no formal education beyond secondary school, have one or more comorbid conditions, have a performance status of 1 or 2 or be over 65 years of age. The patient navigators targeted four phases of treatment: planning, initiation, compliance and end of treatment.

Results: Six months after the start of the study, we had recruited only six patients, due mainly to inherent patient resistance and because only 50% of eligible patients were invited. Of the 18 patients who did not wish to participate, 13 agreed to fill in a baseline questionnaire. The most frequent reason given for not wanting to participate was a belief that a patient navigator would be of no benefit.

Conclusions: The pilot study met a number of internal and external obstacles to patients’ recruitment. The study provides insight into the barriers to recruitment of socially disadvantaged cancer patients to clinical trials and will inform future trial designs.

Acknowledgments

We thank the PACO volunteers for generously donating their time to caring for lung cancer patients.

We also thank Mia Hutters and Sissel Lea Nielsen for providing valuable input during preparation of the content of the intervention and Helle Terkildsen Maindal for providing the score table for the Patient Activation Measure questionnaire.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

The study was supported by the Danish Cancer Society ‘Knæk Cancer’, 2015 [number A4769].